Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma
| Autor: | Yoshinori Imura, Hideaki Sabe, Satoshi Takenaka, Akitomo Inoue, Shigenori Nagata, Hironari Tamiya, Toru Wakamatsu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
business.industry Angiomatoid fibrous histiocytoma medicine.drug_class Neoplasms. Tumors. Oncology. Including cancer and carcinogens Soft tissue Case Report medicine.disease Receptor antagonist Metastasis 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Tocilizumab Oncology chemistry Tumor progression 030220 oncology & carcinogenesis Cancer research Medicine Distant Lymph Node business Autocrine signalling RC254-282 |
| Zdroj: | Case Reports in Oncological Medicine Case Reports in Oncological Medicine, Vol 2021 (2021) |
| ISSN: | 2090-6714 2090-6706 |
| Popis: | Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that rarely metastasizes but lacks effective systemic therapy once it propagates. In some reports, high interleukin-6 (IL-6) production promotes tumor growth by autocrine stimulation and tocilizumab, an IL-6 receptor antagonist, can control AFH growth. Here, we present a case report on a patient with local recurrence and distant lymph node metastasis of AFH treated with tocilizumab. As a result, the inhibition of the IL-6 signaling pathway controlled paraneoplastic inflammatory syndrome (PIS); however, the local recurrent tumor progressed. This case implied that IL-6 is not necessarily the cause of tumor growth in AFH. Therefore, physicians should bear in mind that watchful observation is needed whether tocilizumab can control tumor progression despite the amelioration of PIS associated with the attenuated effect of IL-6 on AFH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text